INTRODUCTION
Immunological cause play an important role in abnormal pregnancy outcome, in which antiphospholipid syndrome is one of the growing cause of concern.
Antiphospholipid syndrome (APS) was first defined as a syndrome in 1983. Consisting of a triad of manifestations involving arterial and/or venous thrombosis, recurrent fetal loss, accompanied by mild to moderate thrombocytopenia and elevated titers of antiphospholipid (APL) antibodies: lupus anticoagulant (LA) and/or anticardiolipin antibodies (aCL). Today, this syndrome is known to be systemic and may affect almost every organ and tissue in the body. The cause of APS is still considered a mystery -yet, as in many other autoimmune diseases, a combination of environmental and genetic factors has been proposed. Recent data indicate that infectious agents may play a major role in the etiology of APS. The pathophysiology of APS includes all arms of the coagulation system. beneficial effect of antithrombotic therapy in APS patients suffering from recurrent pregnancy loss (RPL) suggest a central role for this mechanism in reproductive failure. 2 Antiphospholipid antibodies (aPL) are a heterogeneous group of autoantibodies directed against different antigens, predominantly anionic phospholipids or phospholipid-containing structures. aPL have been associated with pregnancy disorders, including spontaneous miscarriage, recurrent miscarriage, pregnancy-induced hypertension, preeclampsia, and intrauterine growth retardation.
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METHODS
A comparative, cross sectional, observational study was conducted on 250 pregnant patients presenting to the Department of Obstetrics and Gynecology at tertiary care teaching hospital of Rajasthan, India.
They were divided into two groups:
Study group was further divided into 4 groups with 50 pregnant women in each group; (a) history of recurrent abortion; (b) history of IUGR; (c) history of preeclampsia (d) history of preterm labour.
Control group included healthy 50 pregnant woman without any history of miscarriages/ IUGR/ Preeclampsia/pre-term labour.
Method of collection of data was approved from institutional ethics committee was taken before starting the study. The study was explained to them in brief in a language they can understand. Consent of participants was taken in written informed consent form.
Inclusion criteria
 Age -18 to 41 years of age  LMP -12-24 weeks of pregnancy Exclusion criteria  Patients of age less than eighteen years.  Absence of any systemic disease.
The blood sample was collected from these patients and serum sample evaluated for IgG and IgM antibodies against antiphopholipid utilizing ELISA. All data collected were analyzed using appropriate statistical tests.
RESULTS
In our study we found that the maximum percentage of IgG & IgM positivity was in age group of 25-30 year in both case and control group. As gravidity increases, positivity of antiphospholipid increases with in control and cases.
 In group of repeated abortions prevalence of IgG ,IgM was 44% and 30% respectively in case group while in control group & prevalence of IgG, IgM 19% and 10% respectively. Positivity of IgG antiphospholipid antibody is higher in patient with IUGR compare to control group. Strongly positive IgM APA patients were 40%, while in control it was only 16%. Prevalence of IgG antibody in patients with IUGR was 54%, which is much higher than control group (34%).
In preeclamptic patients prevalence of IgG and IgM was 62% and 46%, which was higher than prevalence of IgG (30%) and IgM (23%) in control group. 
DISCUSSION
Age
In accordance in our study Parazzini et al 1991 reported that the maximum number of patients with IgG APA positive were 38% in age group of 25-29 years. 4 Kalra S, Tuli A, Goyal U et al reported that maximum number of IgG APA positive patients of 26-30 years age group is 24%.
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Recurrent fetal loss
It is a known fact that presence of IgG APA is very important risk factor in I st trimester abortion. In our study prevalence rate in case group was 44%. Our observation is in close conformity with a study by Maier DB. Parke A in which prevalence of IgG acl was 30% in the patient with history of recurrent abortion and was found positive in 8% of controls. 6 Creagh MD, Malia RG, Cooper SM et al studied 35 patient with recurrent pregnancy loss out of which 7 were positive for IgG APA. 7 As in above all studies the prevalence of IgG APA is between 11-52.4% in patients of recurrent abortion which is in concordance to our study, where prevalence was around 44%.
In a study by Lockwood et al on 55 patients, it was observed that 18% of recurrent abortions had raised level of IgM APA. 8 Cowchowk et al observed in 75% patients with recurrent abortions had raised levels of IgM APA. 9 Silver et al found the prevalence of IgM ACL 20.4% in their study. 
IUGR
Lima F, Khamshta MA, Buechnan NM, Kerslake S, Hunt BJ, Hughej GR et al showed prevalence of IUGR in their study was 31% in IgG APA positive patients. 14 Clark et al observed that aPL seems to be detectable in 25% of women delivering growth restricted fetuses. 15 
Pre maturity
Lima F, Khamshtha, MA, Buchanan NM, Kerslake S, Hunt BJ showed prevalence of prematurity was 43% in all patients with APA positive. 14 Nossent HC, Swak TJ et al showed the prevalence of prematurity 6-35% of lupus pregnancies.
CONCLUSION
Early autoimmune screening for antiphospholipid antibodies (IgM, IgG) of pregnant ladies was found to be effective tool in predilection of obstetric and fetal complications
